Medicine overview
Indications of Onicoma 10%
Onicoma 10% topical solution is a prescription antifungal medicine indicated for the following:
Established / FDA-approved use
- Treatment of mild to moderate onychomycosis (fungal infection) of the toenails caused by the dermatophytes Trichophyton rubrum and Trichophyton mentagrophytes.
Not established / off-label
- Onicoma 10% has not been adequately studied for fingernail onychomycosis or infections involving the nail matrix/lunula; use for these purposes is not supported by approved labeling and should only be considered on a physician's advice.
Composition
Each pack of Efinaconazole Topical Solution contains Efinaconazole 10% w/w in a colorless, alcohol-containing vehicle formulated to penetrate the nail plate.
Description
Onicoma 10% is a triazole antifungal agent formulated as a topical solution for the treatment of toenail fungal infections. Unlike oral antifungals, Onicoma 10% is applied directly to the affected nail and surrounding skin once daily, allowing localized drug delivery through the nail plate to the underlying nail bed and matrix where the fungus resides.
Therapeutic Class
Onicoma 10% belongs to the therapeutic class of topical antifungal agents, specifically the triazole (azole) antifungal class, used for local treatment of nail fungal infections (onychomycosis).
Pharmacology
Pharmacodynamics
Efinaconazole inhibits fungal lanosterol 14-alpha-demethylase (CYP51), an enzyme required for synthesis of ergosterol, an essential component of the fungal cell membrane. By blocking this enzyme, Efinaconazole disrupts fungal cell membrane synthesis and integrity, producing an antifungal effect against dermatophytes such as Trichophyton rubrum and Trichophyton mentagrophytes.
Pharmacokinetics
Systemic absorption of Efinaconazole after topical application to the toenails is minimal. Plasma concentrations remain low with once-daily application, which limits the potential for systemic adverse effects and drug interactions.
Dosage & Administration of Onicoma 10%
Onicoma 10% topical solution 10% is applied once daily to the affected toenail(s) using the integrated flow-through brush applicator.
| Indication | Dose/Frequency | Typical Duration |
|---|---|---|
| Onychomycosis of the toenails (adults and children 6 years and older) | Apply once daily to clean, dry affected toenail(s) | Up to 48 weeks |
See Administration for detailed application technique and Duration of Treatment for treatment length guidance.
Administration of Onicoma 10%
Using the flow-through brush applicator, apply Onicoma 10% solution evenly to the entire surface of each affected toenail, including the nail bed under the tip of the nail (hyponychium) and the surrounding skin folds, once daily. Nails should be clean and dry before application. Nail polish or other cosmetic nail products should not be used on treated nails during therapy. Allow the solution to dry before putting on socks or footwear. Onicoma 10% is for external use on the toenails only and must not be used orally, in the eyes, or intravaginally.
Interaction of Onicoma 10%
Because systemic absorption of Onicoma 10% after topical application is minimal, no clinically significant drug-drug interactions with systemic medications have been established. Concomitant use of nail polish or other occlusive cosmetic nail products may reduce nail penetration and effectiveness of Onicoma 10% and should be avoided during treatment.
Contraindications
Efinaconazole is contraindicated in patients with known hypersensitivity to Efinaconazole or to any of the excipients in its formulation.
Side Effects of Onicoma 10%
The most commonly reported side effects with Onicoma 10% are local, application-site reactions, including:
- Ingrown toenail
- Application-site dermatitis (redness, irritation)
- Application-site vesicles (small blisters)
- Application-site pain or burning
Rarely, allergic contact dermatitis may occur. If significant irritation, blistering, or signs of an allergic reaction develop, discontinue Onicoma 10% and consult a physician.
Pregnancy & Lactation
Pregnancy: Systemic absorption of Onicoma 10% after topical application is minimal, but adequate, well-controlled studies in pregnant women are lacking. Onicoma 10% should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.
Lactation: It is not known whether topically applied Onicoma 10% is excreted in human milk. Because systemic exposure is minimal, risk to a breastfeeding infant is expected to be low, but a physician should be consulted before using Onicoma 10% while breastfeeding.
Precautions & Warnings
Onicoma 10% topical solution is for external use on the toenails and immediately surrounding skin only. Avoid contact with the eyes, mouth, and other mucous membranes; if accidental contact occurs, rinse thoroughly with water.
The vehicle of Onicoma 10% solution contains flammable (alcohol-based) ingredients; keep away from heat, open flame, and lit cigarettes until the solution has dried on the nail.
Application-site reactions such as dermatitis, vesicles, and ingrown toenail may occur (see Side Effects); discontinue Onicoma 10% and seek medical advice if severe irritation or a hypersensitivity reaction occurs.
Nail polish and other cosmetic nail products should not be used on nails being treated with Onicoma 10%, as they may reduce effectiveness.
Overdose Effects of Onicoma 10%
Onicoma 10% is applied topically in small amounts, so significant systemic overdose is unlikely. If Onicoma 10% solution is accidentally ingested or an excessive amount is applied, seek immediate medical attention or contact a poison control center for further guidance. Do not attempt unsupervised home treatment of a suspected overdose.
Storage Conditions
Store Onicoma 10% topical solution at room temperature (20°C to 25°C / 68°F to 77°F), away from heat, open flame, direct light, and moisture, as the solution vehicle is flammable. Keep the bottle tightly closed and out of reach of children.
Use In Special Populations
Renal Impairment
No dose adjustment of Onicoma 10% is required, as systemic absorption is minimal.
Hepatic Impairment
No dose adjustment of Onicoma 10% is required; formal studies in hepatic impairment have not been conducted, but systemic exposure is expected to remain low.
Elderly
No dose adjustment is required for Onicoma 10% in elderly patients.
Pediatric
See Pediatric Uses for details on the approved age range for Onicoma 10%.
Duration Of Treatment
The typical course of treatment with Onicoma 10% topical solution for toenail onychomycosis is once-daily application for up to 48 weeks. Visible improvement in nail appearance may take several months, since it depends on new, uninfected nail growth; treatment with Onicoma 10% should generally be continued for the full recommended duration even if improvement seems slow, unless a physician advises otherwise.
Drug Classes
Efinaconazole is classified as a topical triazole antifungal agent.
Mode Of Action
Efinaconazole exerts its antifungal effect by inhibiting fungal lanosterol 14-alpha-demethylase (CYP51), a key enzyme in the ergosterol biosynthesis pathway. By blocking ergosterol production, Efinaconazole disrupts the structural integrity and function of the fungal cell membrane, inhibiting fungal growth and ultimately leading to fungal cell death.
Pediatric Uses
Onicoma 10% topical solution is approved for the treatment of toenail onychomycosis in patients 6 years of age and older, based on pharmacokinetic bridging and safety data extrapolated from adult studies. The safety and efficacy of Onicoma 10% in children younger than 6 years have not been established, and use in this age group is not recommended outside of physician guidance.
Frequently Asked Questions
Q: What is Onicoma 10% 8 ml Topical Solution used for?
A: Onicoma 10% 8 ml Topical Solution topical solution is used to treat toenail fungal infection (onychomycosis) caused by Trichophyton rubrum and Trichophyton mentagrophytes. It is applied directly to the affected toenail once daily.
Q: How long do I need to use Onicoma 10% 8 ml Topical Solution?
A: Treatment with Onicoma 10% 8 ml Topical Solution typically continues once daily for up to 48 weeks, since nails grow slowly and full clearance depends on new, healthy nail growth. Do not stop early without consulting your physician.
Q: Can I wear nail polish while using Onicoma 10% 8 ml Topical Solution?
A: No. Nail polish and other cosmetic nail products can block Onicoma 10% 8 ml Topical Solution from penetrating the nail and reduce its effectiveness, so they should be avoided on nails being treated.
Q: Is Onicoma 10% 8 ml Topical Solution safe to use during pregnancy or breastfeeding?
A: Onicoma 10% 8 ml Topical Solution has minimal systemic absorption after topical use, but adequate studies in pregnant or breastfeeding women are lacking. It should be used during pregnancy only if clearly needed, when the potential benefit outweighs the potential risk, and a physician should be consulted before use while pregnant or breastfeeding.
Q: What side effects can Onicoma 10% 8 ml Topical Solution cause?
A: The most common side effects of Onicoma 10% 8 ml Topical Solution are local application-site reactions, including ingrown toenail, dermatitis (redness/irritation), small blisters (vesicles), and pain or burning at the application site. Rarely, allergic contact dermatitis can occur; if severe irritation, blistering, or allergic symptoms develop, stop using Onicoma 10% 8 ml Topical Solution and contact a physician.
Q: What should I do if Onicoma 10% 8 ml Topical Solution is accidentally swallowed?
A: Accidental ingestion of Onicoma 10% 8 ml Topical Solution solution is unlikely to cause serious systemic effects because so little is absorbed, but you should seek immediate medical attention or contact a poison control center as a precaution, and avoid unsupervised home treatment.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
